Cell and gene therapy (CGT) represents one of the most exciting frontiers in medicine, potentially unlocking cures and offering improvements on existing treatments. But while the science behind these therapies is groundbreaking, getting them from the lab to the patient presents an entirely different set of challenges: ones that demand precision, teamwork, and problem-solving at an entirely new level.
Whether you’re a researcher or a process development scientist, it’s easy to underestimate the complexity of shipment packaging, even though it’s the last line of defense between the success of the life-saving therapy you’re responsible for, and disaster.
Even if you’re a seasoned supply chain professional who thinks they’ve seen it all (first-mile logistics temperature excursions, broken drug product bags, last-mile shipments arriving with no temperature readings), suddenly you might have to find solutions to challenges no one’s ever faced before – because CGT logistics are very different, and still in their infancy.
From qualifying infusion sites to maintaining temperature-sensitive viral vectors by controlling supercooling events, to ensuring your cloud-based condition monitoring system actually works when you need it most, every step requires innovation, adaptability and a deep understanding of supply chain intricacies, partnerships both across departments, and with critical suppliers and knowledge partners.
This is the first in a series of blogs that will explore the most pressing challenges in CGT cold chain logistics, from first-mile apheresis collection to last-mile infusion site delivery. We’ll unpack the hidden pitfalls, highlight real-world case studies, and provide insights that could make the difference between success and failure.
While the blogs will focus primarily on CAR-T therapies, gene therapies will not be overlooked.
Where CAR-T therapy diverges from both traditional biopharma and gene therapies is in the first-mile logistics, specifically the collection of apheresis or starting materials. This early-stage complexity sets CAR-T apart, while gene and cell therapies share more similarities in the last-mile logistics, particularly in the delivery to healthcare facilities for patient infusion.
In many ways, gene therapies follow traditional cold chain manufacturing paths, producing larger batches or products ready to ship when a patient needs them. However, gene therapies face specific challenges due to their temperature requirements, needing to be shipped on dry ice, which can make those shipments sensitive to supercooling.
From there, cell and gene therapies have a lot in common in their direct-to-patient/hospital/infusion site requirements and challenges, including the need to be released with no temperature excursions prior to infusion.
Defining Cell and Gene Therapy
First, let’s clear up a common misconception: Cell & Gene Therapy is often used like it’s one big, singular thing. It’s not. These are two distinct yet overlapping treatment approaches, and while they share some logistical challenges, the where and how of modifying a patient’s cells are worlds apart-driving wildly different supply chain demands.
Understanding the basics of these therapies is key to grasping the logistics and packaging challenges ahead.
At their core, both therapies rely on delivery vehicles; most often in commercialized products today, viral vectors are used, which are essentially genetically modified viruses that act as microscopic delivery drivers. That said, non-viral options like lipid nanoparticles and other options are rapidly emerging.
No matter what therapy method is used, instead of these delivery vehicles dropping off a package on your doorstep, they’re delivering genetic instructions to cells, enabling them to fight or correct diseased cells whether by adding, editing, or silencing genes.
In cell therapy, the dominant model is an autologous CAR-T process, where a patient’s cells are collected, shipped off to a manufacturing facility, modified outside the body (ex vivo), and eventually sent back for infusion into the patient. The viral vectors used for this process – Retroviral Vectors (RVV) and Lentiviral Vectors (LVV) – help reprogram the patient’s own cells to fight disease.
However, other technologies are emerging including non-viral approaches like electroporation for CRISPER-based editing, and allogeneic platforms such as CAR-NK cells or iPSC derived CAR-T. Thes often use healthy donor or renewable cells sources (allogenic), enabling production of off-the-shelf batches instead of today’s personalized autologous processes-potentially simplifying future supply chains through scalability, and faster turnaround times.
Gene therapy, on the other hand, often skips the external part. Instead of modifying cells outside the body, gene therapy delivers genetic material directly to the patient cells inside the body (in vivo), most commonly using a viral vector (typically an Adeno-Associated Virus, or AAV). The manufacturer produces the delivery vehicle in their facility, then ships it directly to the treatment site: whether that’s a hospital, clinic, or infusion center.
In this series, we'll zero in on today's dominant models: autologous CAR-T, primarily using RVV and LVV Vectors, and AAV-based gene therapies. These drive the field's most acute logistical challenges. Emerging alternatives may ease some burdens in the future, but the core issues, including time-sensitive viability, challenges due to cryogenic shipping, personalized tracking and coordination complexity, persist across generations of CGT.
Cell & Gene Therapy Is a Team Sport
A former CEO at an industry-leading CGT company used to say, “Cell & Gene Therapy is a team sport.”
That isn’t hyperbole. CGT demands deep, cross-functional collaboration, with multiple departments and external vendors. The level of teamwork required is unparalleled, and the need to have knowledgeable partners and resources available is critical.
Managers and teams need to foster strong, ongoing communication, align processes with their cross-functional counterparts, and their supplier base of critical packaging components. Silos don’t just slow things down;, but can create real risks that can impact patient outcomes.
High-level logistics networks
Many like to depict the process as a circular flow, and sure, that makes sense, since for CAR-T therapies, the process starts with the patient at apheresis and ends with the patient receiving their infusion. But here at CCT, we prefer triangles – specifically, the vein-to-vein triangle – which best captures the reality of how CGT moves.
